General Biologicals Corp.(TW:4117)
NT$7.41-0.39 (-5.00%)
TW:4117
General Biologicals Corp. financials statements
NT$7.41
At close:-0.39 (-5.00%)
General Biologicals Corp. (4117) Ratios
General Biologicals Corp. Ratios
TW:4117's free cash flow for Q2 2026 was NT$-55.19M. For the 2026 fiscal year, TW:4117's free cash flow was decreased by NT$-6.66M and operating cash flow was NT$-48.52M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.00 | 0.99 | 0.39 | 5.62 | 6.62 |
| Quick Ratio | 1.85 | 0.86 | 0.31 | 4.43 | 5.57 |
| Cash Ratio | 0.61 | 0.56 | 0.21 | 2.67 | 4.01 |
| Solvency Ratio | 0.14 | -0.06 | -0.08 | -0.02 | 0.15 |
| Operating Cash Flow Ratio | -0.32 | -0.26 | 0.22 | 2.30 | 0.51 |
| Short-Term Operating Cash Flow Coverage | -1.07 | -1.15 | 4.29 | 28.53 | 4.89 |
| Net Current Asset Value | NT$ -3.20B | NT$ -2.67B | NT$ -1.64B | NT$ -306.53M | NT$ -19.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.68 | 0.22 | 0.30 | 0.36 |
| Debt-to-Equity Ratio | 2.87 | 8.12 | 1.11 | 0.68 | 0.62 |
| Debt-to-Capital Ratio | 0.74 | 0.89 | 0.53 | 0.41 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.69 | 0.86 | 0.06 | 0.00 | 0.00 |
| Financial Leverage Ratio | 5.59 | 11.97 | 5.12 | 2.25 | 1.73 |
| Debt Service Coverage Ratio | 4.07 | -1.49 | -2.34 | 0.01 | 4.79 |
| Interest Coverage Ratio | -11.07 | -15.95 | -14.18 | -2.42 | 3.98 |
| Debt to Market Cap | 2.71 | 1.43 | 0.05 | 0.00 | 0.00 |
| Interest Debt Per Share | 42.06 | 38.83 | 9.39 | 8.14 | 7.78 |
| Net Debt to EBITDA | 3.73 | -12.06 | -2.39 | 26.03 | 1.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 27.63% | 2.99% | 23.68% | 46.39% | 51.11% |
| EBIT Margin | 243.46% | -82.86% | -66.36% | -7.54% | 8.99% |
| EBITDA Margin | 280.11% | -67.76% | -52.51% | 2.16% | 15.47% |
| Operating Profit Margin | -101.22% | -84.61% | -64.17% | -11.03% | 7.94% |
| Pretax Profit Margin | 234.31% | -88.17% | -70.88% | -12.45% | 7.00% |
| Net Profit Margin | 215.93% | -87.65% | -75.08% | -14.36% | 8.00% |
| Continuous Operations Profit Margin | 215.46% | -87.95% | -75.46% | -14.53% | 7.99% |
| Net Income Per EBT | 92.15% | 99.42% | 105.92% | 115.32% | 114.34% |
| EBT Per EBIT | -231.49% | 104.21% | 110.46% | 112.86% | 88.16% |
| Return on Assets (ROA) | 9.57% | -6.48% | -7.84% | -3.43% | 3.49% |
| Return on Equity (ROE) | 53.50% | -77.59% | -40.16% | -7.70% | 6.03% |
| Return on Capital Employed (ROCE) | -4.88% | -7.21% | -11.27% | -2.81% | 3.69% |
| Return on Invested Capital (ROIC) | -4.37% | -6.73% | -10.12% | -2.78% | 3.64% |
| Return on Tangible Assets | 9.67% | -6.59% | -8.02% | -3.57% | 3.68% |
| Earnings Yield | 60.60% | -17.62% | -12.31% | -3.28% | 2.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.01 | 2.58 | 3.11 | 6.02 | 11.62 |
| Payables Turnover | 2.55 | 2.95 | 8.71 | 8.28 | 7.93 |
| Inventory Turnover | 2.65 | 4.28 | 2.36 | 1.70 | 3.32 |
| Fixed Asset Turnover | 0.26 | 0.09 | 0.13 | 0.43 | 0.91 |
| Asset Turnover | 0.04 | 0.07 | 0.10 | 0.24 | 0.44 |
| Working Capital Turnover Ratio | 1.10 | -0.80 | -3.04 | 0.84 | 1.15 |
| Cash Conversion Cycle | 115.82 | 103.37 | 229.87 | 231.14 | 95.45 |
| Days of Sales Outstanding | 121.10 | 141.67 | 117.27 | 60.59 | 31.42 |
| Days of Inventory Outstanding | 137.83 | 85.24 | 154.50 | 214.64 | 110.05 |
| Days of Payables Outstanding | 143.10 | 123.54 | 41.90 | 44.09 | 46.02 |
| Operating Cycle | 258.92 | 226.91 | 271.77 | 275.23 | 141.46 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.13 | -1.94 | 3.77 | 3.76 | 0.65 |
| Free Cash Flow Per Share | -5.06 | -27.39 | -3.33 | -0.39 | -1.44 |
| Dividend Paid and CapEx Coverage Ratio | -0.72 | -0.08 | 0.53 | 0.91 | 0.31 |
| Capital Expenditure Coverage Ratio | -0.72 | -0.08 | 0.53 | 0.91 | 0.31 |
| Operating Cash Flow Coverage Ratio | -0.05 | -0.05 | 0.41 | 0.48 | 0.09 |
| Operating Cash Flow to Sales Ratio | -0.59 | -0.46 | 0.85 | 0.61 | 0.07 |
| Free Cash Flow Yield | -39.39% | -130.72% | -12.34% | -1.46% | -4.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 1.65 | -5.68 | -8.13 | -30.45 | 47.30 |
| Price-to-Sales (P/S) Ratio | 3.56 | 4.98 | 6.10 | 4.38 | 3.80 |
| Price-to-Book (P/B) Ratio | 0.88 | 4.40 | 3.26 | 2.35 | 2.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.54 | -0.77 | -8.10 | -68.70 | -24.39 |
| Price-to-Operating Cash Flow Ratio | -6.04 | -10.79 | 7.16 | 7.21 | 53.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | -0.51 | -0.03 | 0.14 | -1.27 |
| Enterprise Value Multiple | 5.00 | -19.40 | -14.01 | 228.97 | 26.24 |
| Enterprise Value | 3.02B | 3.31B | 1.95B | 1.83B | 2.24B |
| EV to EBITDA | 5.00 | -19.40 | -14.01 | 228.97 | 26.24 |
| EV to Sales | 14.01 | 13.14 | 7.35 | 4.94 | 4.06 |
| EV to Free Cash Flow | -9.98 | -2.02 | -9.77 | -77.51 | -26.08 |
| EV to Operating Cash Flow | -23.74 | -28.52 | 8.63 | 8.13 | 57.46 |
| Tangible Book Value Per Share | 13.71 | 3.88 | 7.35 | 10.55 | 11.19 |
| Shareholders’ Equity Per Share | 14.55 | 4.76 | 8.28 | 11.54 | 12.23 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.00 | -0.06 | -0.17 | -0.14 |
| Revenue Per Share | 3.61 | 4.21 | 4.43 | 6.19 | 9.22 |
| Net Income Per Share | 7.79 | -3.69 | -3.32 | -0.89 | 0.74 |
| Tax Burden | 0.92 | 0.99 | 1.06 | 1.15 | 1.14 |
| Interest Burden | 0.96 | 1.06 | 1.07 | 1.65 | 0.78 |
| Research & Development to Revenue | 0.30 | 0.20 | 0.13 | 0.10 | 0.06 |
| SG&A to Revenue | 0.96 | 0.68 | 0.76 | 0.49 | 0.40 |
| Stock-Based Compensation to Revenue | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.25 | 0.52 | -1.20 | -4.88 | 0.88 |
Currency in TWD
